Literature DB >> 7451612

Simultaneous determination of d- and l-propranolol in human plasma by high-performance liquid chromatography.

J Hermansson, C von Bahr.   

Abstract

A method for the determination of d- and l-propranolol in human plasma is described. The method involves extraction of propranolol from plasma, and the formation of diastereomeric derivatives with the chiral reagent N-trifluoroacetyl-1-prolylchloride. Separation and quantitation of the diastereomeric propranolol derivatives are carried out by a reversed-phase high-performance liquid-chromatographic system with fluorimetric detection. The reproducibility in the determination of d- and l-propranolol in human plasma was 4.5% (relative standard deviation) at drug levels of 10 ng/ml. In two subjects who received a single 40-mg tablet of racemic propranolol the plasma levels of the d-isomer were lower than of the l-propranolol. The half-lives of d- and l-propranolol were similar.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7451612     DOI: 10.1016/s0378-4347(00)81012-9

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Chiral amines derived from 2-arylpropionic acids: novel reagents for the liquid chromatographic (LC) fluorescence assay of optically active carboxylic acid xenobiotics.

Authors:  H Spahn; P Langguth
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

3.  Enantiospecific high-performance liquid chromatographic (HPLC) determination of baclofen and its fluoro analogue in biological material.

Authors:  H Spahn; D Krauss; E Mutschler
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

4.  Measurement of underivatized propranolol enantiomers in serum using a cellulose-tris(3,5-dimethylphenylcarbamate) high-performance liquid chromatographic (HPLC) chiral stationary phase.

Authors:  R J Straka; R L Lalonde; I W Wainer
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

5.  Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.

Authors:  R J Francis; P B East; J Larman
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man.

Authors:  C Von Bahr; J Hermansson; K Tawara
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

Review 7.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

8.  Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.

Authors:  K Tawara; K Kawashima; H Ishikawa; K Yamamoto; K Saito; A Ebihara; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.